Form 13-F position report

FORTE BIOSCIENCES

Reported by GEODE CAPITAL MANAGEMENT LLC

FBRX CUSIP 34962G109 Manager CIK 0001214717

Reported 346,292 shares, up 2,860 (0.8%) from the prior quarter.

Reported value -22.7%; share count 0.8% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 346,292 Quarter-end amount reported
Reported value $186,008 Fair value at quarter end
Consecutive quarters held 17 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 300000
2021-12-31 546000
2022-03-31 375000
2022-06-30 242000
2022-09-30 204000
2022-12-31 192000
2023-03-31 195121
2023-06-30 201066
2023-09-30 138009
2023-12-31 276656
2024-03-31 240705
2024-06-30 186008
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for FORTE BIOSCIENCES held by GEODE CAPITAL MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -346,292 (-100.0%) 0 $0 2024-11-12
Q2 2024 Added 346,292 +2,860 (0.8%) < 0.01% $186,008 2024-08-09
Q1 2024 Added 343,432 +6,827 (2.0%) < 0.01% $240,705 2024-05-13
Q4 2023 Added 336,605 +128,222 (61.5%) < 0.01% $276,656 2024-02-13
Q3 2023 Added 208,383 +15,050 (7.8%) < 0.01% $138,009 2023-11-13
Q2 2023 Added 193,333 +143 (0.1%) < 0.01% $201,066 2023-08-11
Q1 2023 Added 193,190 +742 (0.4%) < 0.01% $195,121 2023-05-15
Q4 2022 Added 192,448 +1,395 (0.7%) < 0.01% $192,000 2023-02-13
Q3 2022 Added 191,053 +4,455 (2.4%) < 0.01% $204,000 2022-11-14
Q2 2022 Reduced 186,598 -70,288 (-27.4%) < 0.01% $242,000 2022-08-12
Q1 2022 Added 256,886 +1,415 (0.6%) < 0.01% $375,000 2022-05-13
Q4 2021 Added 255,471 +154,086 (152.0%) < 0.01% $546,000 2022-02-11
Q3 2021 Reduced 101,385 -77,053 (-43.2%) < 0.01% $300,000 2021-11-12
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

38 managers reported FORTE BIOSCIENCES for Q2 2024.

Managers reporting FORTE BIOSCIENCES in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
TYBOURNE CAPITAL MANAGEMENT HK LTD Unchanged 3,624,548 0 0.4% $1,946,383 4 qtrs
PERCEPTIVE ADVISORS LLC Unchanged 3,265,359 0 0.04% $1,753,498 4 qtrs
BVF INC IL Unchanged 2,982,105 0 0.04% $1,601,390 4 qtrs
Cable Car Capital LP Unchanged 2,031,987 0 1.15% $1,091,177 3 qtrs
FRED ALGER MANAGEMENT LLC Unchanged 1,838,965 0 < 0.01% $987,524 4 qtrs
FARALLON CAPITAL MANAGEMENT LLC Unchanged 1,810,455 0 < 0.01% $972,214 4 qtrs
BML Capital Management LLC Unchanged 1,761,702 0 0.68% $946,034 7 qtrs
VANGUARD GROUP INC Unchanged 665,230 0 < 0.01% $357,228 17 qtrs
GEODE CAPITAL MANAGEMENT LLC This report Added 346,292 +2,860 < 0.01% $186,008 17 qtrs
BlackRock Inc Unchanged 174,858 0 < 0.01% $93,899 17 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 09, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
346,292
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.